Annexon Inc (ANNX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Annexon Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.10 $ — 61% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 41.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 212 m net cash passed
- Operating cash flow covers the profits of the last three years 54 m failed
- Return on capital at 15% or higher, or up versus two years ago -92.1% failed
- Insiders hold at least 10% or are net buyers 0.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 159.8% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.99 | -1.14 – -0.86 | 0 | 26.2% | 6 |
| 12/31/2027 | -0.99 | -1.28 – -0.64 | 40 | -0.4% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.23 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.33 | – | 3 | -30.00 | -1,427.40 | -36 | -36 |
| 2025: Q1 | -0.37 | – | 0 | – | – | -50 | -50 |
| 2025: Q2 | -0.33 | – | 0 | – | – | -38 | -38 |
| 2025: Q3 | -0.37 | – | 0 | – | – | -52 | -52 |
| 2025: Q4 | -0.31 | – | 0 | -100.00 | – | -46 | -46 |
| 2026: Q1 | -0.23 | – | 0 | – | – | -47 | -47 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | – | -20 | -19 | -0.49 | -19 | -46 | 8 |
| 2018 | 0 | -19 | -18 | -1.60 | -17 | 38 | 48 |
| 2019 | 0 | -33 | -37 | -0.97 | -28 | 44 | 50 |
| 2020 | 0 | -63 | -63 | -3.70 | -53 | 344 | 356 |
| 2021 | 0 | -131 | -128 | -3.34 | -106 | 232 | 287 |
| 2022 | 0 | -146 | -138 | -2.53 | -116 | 231 | 285 |
| 2023 | 0 | -144 | -134 | -1.77 | -121 | 251 | 298 |
| 2024 | 0 | -154 | -138 | -1.01 | -118 | 293 | 350 |
| 2025 | 0 | -216 | -207 | -1.33 | -186 | 212 | 278 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Annexon, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entdeckt und entwickelt Medikamente zur Behandlung entzündungsbedingter Erkrankungen.
| Employees | 93 |
|---|---|
| Headquarters | Brisbane, CA |
| Address | 1400 Sierra Point Parkway, 94005 Brisbane, United States |
| Phone | 650 822 5500 |
| Website | annexonbio.com |
| IPO Date | 24. Jul 2020 |
| ISIN | US03589W1027 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Douglas E. Love Esq., J.D. | CEO, President & Director | 1968 |
| Jennifer Lew CPA | Executive VP, CFO & Corporate Secretary | 1973 |
| Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 1958 |
| Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 1961 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.